[Featured Stock] Paksel Bio Surges on Expectations for Phase 2a Clinical Trial Results of Liver Cancer Treatment

[Asia Economy Reporter Junho Hwang] Parksel Bio's stock price is surging in early trading. As of 9:36 AM on the 1st, Parksel Bio is trading at 81,300 KRW, up 8,000 KRW (11.24%) from the previous trading day.

Earlier, preliminary results from the Phase 2a clinical trial of Parksel Bio's Vax-NK/HCC combined with HAIC therapy were disclosed through a poster at the Korean Society of Medical Oncology (KSMO 2022) international academic event.

A Parksel Bio representative explained, "We announced encouraging results such as an Objective Response Rate (ORR) of 66.7% and a Disease Control Rate (DCR) of 100%, once again proving our technological capabilities as a company specializing in cancer immunotherapy development."

Vax-NK/HCC is an autologous cancer immunotherapy cell treatment currently under clinical research by Parksel Bio. It is being studied in a Phase 2a clinical trial involving 20 patients at five university hospitals nationwide, targeting advanced liver cancer, which has a poor prognosis among liver cancers.

Parksel Bio's combined therapy of Vax-NK/HCC and HAIC had previously attracted attention with Phase 1 clinical trial results. The study, involving 11 patients, showed an Objective Response Rate of 63.6%, with 4 Complete Responses (CR) and 3 Partial Responses (PR).

This content was produced with the assistance of AI translation services.